UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature

Leukemia & lymphoma, 2016-03, Vol.57 (3), p.735-737

2016

Volltextzugriff (PDF)

Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients

Leukemia & lymphoma, 2018-11, Vol.59 (11), p.2734-2736

2018

Volltextzugriff (PDF)

A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients

Leukemia & lymphoma, 2019-02, Vol.60 (3), p.845-847

2019

Volltextzugriff (PDF)

The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis

Leukemia & lymphoma, 2019-06, Vol.60 (7), p.1644-1649

2019

Volltextzugriff (PDF)

Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)

Leukemia & lymphoma, 2017-07, Vol.58 (7), p.1736-1739

2017

Volltextzugriff (PDF)

Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis

Blood, 2018-01, Vol.131 (3), p.365-368

2018

Volltextzugriff (PDF)

Reliability of six prognostic models to predict time‐to‐first‐treatment in patients with chronic lymphocytic leukaemia in early phase

American journal of hematology, 2017-06, Vol.92 (6), p.E91-E93

2017

Volltextzugriff (PDF)

The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients

American journal of hematology, 2016-11, Vol.91 (11), p.1090-1095

2016

Volltextzugriff (PDF)

Intracerebral immunotherapy for brain tumors

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e13522-e13522

2019

Volltextzugriff (PDF)

A Simple Score, Based on Geriatric Assessment, Predicts Survival in Elderly Newly Diagnosed Chronic Lymphocytic Leukemia Patients

Blood, 2016-12, Vol.128 (22), p.2036-2036

2016

Volltextzugriff (PDF)

Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis

Blood, 2015-12, Vol.126 (23), p.498-498

2015

Volltextzugriff (PDF)

Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model

European journal of haematology, 2016-01, Vol.96 (1), p.72-77

2016

Volltextzugriff (PDF)

Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?

Advances in Hematology, 2009, Vol.2009 (2009), p.55-60

2009

Volltextzugriff (PDF)

Exclusion of SERUM Thymidine Kinase Does NOT Reduce the Predictive VALUE of a Comprehensive Prognostic INDEX in Chonic Lymphocytic Leukemia. Results of an External Validation on a Prospective Cohort of Patients with EARLY Disease

Blood, 2014-12, Vol.124 (21), p.4692-4692

2014

Volltextzugriff (PDF)

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

International journal of cancer, 2020-04, Vol.146 (7), p.1917-1929

2020

Volltextzugriff (PDF)

Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines

Expert review of hematology, 2014-10, Vol.7 (5), p.691-695

2014

Volltextzugriff (PDF)

VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Blood, 2011-11, Vol.118 (21), p.4601-4601

2011

Volltextzugriff (PDF)

Characteristics and outcome of B-cell chronic lymphocytic leukemia in hepatitis C virus-positive patients

Leukemia & lymphoma, 2006-11, Vol.47 (11), p.2421-2423

2006

Volltextzugriff (PDF)

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Blood, 2008-11, Vol.112 (11), p.4158-4158

2008

Volltextzugriff (PDF)

Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia

Haematologica (Roma), 2007-10, Vol.92 (10), p.1367-1374

2007

Volltextzugriff (PDF)

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Blood, 2008-11, Vol.112 (11), p.4187-4187

2008

Volltextzugriff (PDF)

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia

Blood, 2007-11, Vol.110 (11), p.3093-3093

2007

Volltextzugriff (PDF)

Characteristics and Outcome of B-Cell Chronic Lymphocytic Leukemia in HCV-Positive Patients

Blood, 2005-11, Vol.106 (11), p.4986-4986

2005

Volltextzugriff (PDF)

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia

Blood, 2006-11, Vol.108 (11), p.2786-2786

2006

Volltextzugriff (PDF)

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Blood, 2010-11, Vol.116 (21), p.2471-2471

2010

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

ThemaDisease Progression

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(41)
Berichte
(1)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

Science & Technology
(22)
Life Sciences & Biomedicine
(21)
Humans
(20)
Middle Aged
(17)
Female
(16)
Male
(15)
Aged
(14)
Hematology
(13)
Prognosis
(10)
Adult
(9)
Oncology
(9)
Aged, 80 And Over
(8)
Leukemia, Lymphocytic, Chronic, B-Cell - Diagnosis
(7)
Neurosciences
(7)
Neurosciences & Neurology
(7)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(6)
Mutation - Genetics
(6)
Italy
(5)
Alzheimer Disease - Genetics
(4)
Leukemia, Lymphocytic, Chronic, B-Cell - Pathology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature

Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients

A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients

The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis

Assessing time to first treatment in early chronic lymphocytic leukemia (CLL): a comparative performance analysis of five prognostic models with inclusion of CLL-international prognostic index (CLL-IPI)

Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis

Reliability of six prognostic models to predict time‐to‐first‐treatment in patients with chronic lymphocytic leukaemia in early phase

The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients

Intracerebral immunotherapy for brain tumors

A Simple Score, Based on Geriatric Assessment, Predicts Survival in Elderly Newly Diagnosed Chronic Lymphocytic Leukemia Patients

Is the International Prognostic INDEX for CLL (CLL-IPI) Useful to Predict Time to First Treatment of Patients with EARLY Disease? Results of a Prospective Multicenter Analysis

Unavailability of thymidine kinase does not preclude the use of German comprehensive prognostic index: results of an external validation analysis in early chronic lymphocytic leukemia and comparison with MD Anderson Cancer Center model

Does Adiponectin Act as an Antiangiogenic Factor in B-Cell Chronic Lymphocytic Leukemia?

Exclusion of SERUM Thymidine Kinase Does NOT Reduce the Predictive VALUE of a Comprehensive Prognostic INDEX in Chonic Lymphocytic Leukemia. Results of an External Validation on a Prospective Cohort of Patients with EARLY Disease

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

Changes in the incidence, pattern of presentation and clinical outcome of early chronic lymphocytic leukemia patients using the 2008 International Workshop on CLL guidelines

VITAMIN D Insufficiency Affects Time to FIRST TREATMENT (TFT) In EARLY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

Characteristics and outcome of B-cell chronic lymphocytic leukemia in hepatitis C virus-positive patients

Serum BAFF (B-CELL Activating Factor Of The TNF Family) predicts time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia

Serum CD26 (Dipeptidyl Peptidase IV, DPP IV) compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-CELL Chronic Lymphocytic Leukemia

Serum BAFF (B-Cell Activating Factor of the TNF Family) Compared with Immunoglobulin Heavy-Chain Mutation Status, ZAP-70 and CD38 as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia

Characteristics and Outcome of B-Cell Chronic Lymphocytic Leukemia in HCV-Positive Patients

Serum Adiponectin Compared with ZAP-70, CD38 and Immunoglobulin Heavy-Chain Mutation Status as a Predictor of Time to First Treatment in Early B-Cell Chronic Lymphocytic Leukemia

Efficacy and Safety of a First Line Combined Therapeutic Approach for Young CLL Patients with Advanced or Progressive Disease Stratified According to the Biologic Features: First Analysis of the GIMEMA Multicenter Study LLC0405

Aktive Filter

Suchergebnisse filtern